Intellia Therapeutics (NTLA) Current Leases (2019 - 2026)

Intellia Therapeutics (NTLA) has 8 years of Current Leases data on file, last reported at $19.1 million in Q1 2026.

• Current Leases for Q1 2026 came in at $19.1 million, down 50.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.1 million (down 50.74% YoY), and the FY2025 annual result was $26.5 million, up 30.79% from the prior year.
• Current Leases retreated to $19.1 million in Q1 2026 per NTLA's latest filing, from $26.5 million in the prior quarter.
• Over five years, Current Leases peaked at $38.8 million in Q1 2025 and troughed at $9.3 million in Q1 2022.
• A 5-year average of $19.6 million and a median of $18.8 million in 2024 frame the typical range for Current Leases.
• The sharpest annual moves came in 2025 and 2026: Current Leases surged 106.59% in 2025, then plunged 50.74% in 2026.
• A 5-year view of Current Leases shows it stood at $16.7 million in 2022, then rose by 11.47% to $18.6 million in 2023, then advanced by 8.86% to $20.2 million in 2024, then soared by 30.79% to $26.5 million in 2025, then decreased by 27.89% to $19.1 million in 2026.
• Business Quant data shows NTLA's Current Leases at $19.1 million in Q1 2026, $26.5 million in Q4 2025, and $27.4 million in Q3 2025.